Cyclotides as Drug Scaffolds: Ultra-Stable Natural Peptides for Engineering New Medicines
Cyclotides' exceptional stability (resistant to heat, enzymes, and chemicals) combined with their amenability to sequence grafting makes them ideal scaffolds for creating a new class of stable peptide drugs.
Quick Facts
What This Study Found
Cyclotides combine exceptional structural stability (thermal, enzymatic, chemical resistance) with sequence-tolerant scaffolding capability, enabling design of stable peptide drugs through grafting bioactive sequences into the cyclotide framework.
Key Numbers
How They Did This
Review of cyclotide discovery, structural biology, stability properties, known bioactivities, and drug design applications including grafting strategies.
Why This Research Matters
Most peptide drugs fail because they're unstable in the body. Cyclotides solve this stability problem while maintaining the ability to present drug-like sequences, potentially enabling oral peptide drugs.
The Bigger Picture
Cyclotides represent a paradigm shift in peptide drug development. Instead of fighting peptide instability with chemical modifications, nature has provided a ready-made stable scaffold that drugs can be built upon.
What This Study Doesn't Tell Us
Drug design with cyclotides was still in early stages. Not all bioactive sequences can be successfully grafted. Manufacturing at pharmaceutical scale is challenging.
Questions This Raises
- ?Can cyclotide-grafted drugs achieve oral bioavailability?
- ?Which therapeutic areas benefit most from cyclotide scaffolding?
- ?Can cyclotides be produced cost-effectively for pharmaceutical use?
Trust & Context
- Key Stat:
- Nature's scaffold Cyclotides resist heat, enzymes, and chemicals while allowing drug sequences to be grafted in — nature solved the peptide stability problem
- Evidence Grade:
- Moderate evidence from a review synthesizing structural, stability, and early drug design data for cyclotide scaffolds.
- Study Age:
- Published in 2002. Cyclotide drug design has advanced enormously, with grafted cyclotides now in preclinical development for cancer, pain, and cardiovascular diseases.
- Original Title:
- The cyclotides: novel macrocyclic peptides as scaffolds in drug design.
- Published In:
- Current opinion in drug discovery & development, 5(2), 251-60 (2002)
- Authors:
- Craik, David J(14), Simonsen, Shane, Daly, Norelle L(9)
- Database ID:
- RPEP-00721
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What makes cyclotides special for drug design?
Most peptide drugs break down in minutes in the body. Cyclotides survive heat, stomach acid, and digestive enzymes due to their circular backbone and knotted structure. This means drugs built on cyclotide scaffolds could be taken as pills.
What diseases could cyclotide drugs treat?
Potentially many. By grafting drug-like sequences into the stable cyclotide framework, researchers are developing candidates for cancer, cardiovascular disease, pain, and metabolic disorders — any condition where a stable peptide drug would be beneficial.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00721APA
Craik, David J; Simonsen, Shane; Daly, Norelle L. (2002). The cyclotides: novel macrocyclic peptides as scaffolds in drug design.. Current opinion in drug discovery & development, 5(2), 251-60.
MLA
Craik, David J, et al. "The cyclotides: novel macrocyclic peptides as scaffolds in drug design.." Current opinion in drug discovery & development, 2002.
RethinkPeptides
RethinkPeptides Research Database. "The cyclotides: novel macrocyclic peptides as scaffolds in d..." RPEP-00721. Retrieved from https://rethinkpeptides.com/research/craik-2002-the-cyclotides-novel-macrocyclic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.